Allogene Therapeutics, Inc. (ALLO)

Name: Allogene Therapeutics, Inc. (ALLO) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001737287 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Allogene Therapeutics, Inc. reported revenue of $0. Revenue fell 100.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $4.64M.

Key ratios (year ended 2025-12-31)

-65.3%

Return on year-end equity

-100.0%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31
Revenue	$4.64M	$0	$22.0K	$95.0K	n/a	n/a	n/a	$156.0K	n/a	n/a	n/a
R&D Expense	$122.52M	$150.15M	$192.30M	$242.91M	n/a	n/a	n/a	$256.39M	n/a	n/a	n/a
Operating Income	-$180.32M	-$209.31M	-$273.20M	-$327.74M	n/a	n/a	n/a	-$335.54M	n/a	n/a	n/a
Depreciation & Amortization	$11.67M	$12.36M	$13.64M	$14.20M	n/a	n/a	n/a	$14.30M	n/a	n/a	n/a
EBITDA	-$168.65M	-$196.96M	-$259.56M	-$313.54M	n/a	n/a	n/a	-$321.24M	n/a	n/a	n/a
Net Income	-$165.49M	-$190.89M	-$257.59M	-$327.26M	n/a	n/a	n/a	-$340.41M	n/a	n/a	n/a
EPS (Diluted)	n/a	-$0.87	-$1.32	-$2.09	n/a	n/a	n/a	-$2.38	n/a	n/a	n/a
Total Assets	$550.09M	$415.90M	$548.71M	$642.84M	$713.41M	$773.01M	$750.13M	$821.58M	$894.48M	$955.62M	$978.09M
Total Liabilities	$113.92M	$123.36M	$126.53M	$130.60M	$132.78M	$151.60M	$158.12M	$154.70M	$151.08M	$149.14M	$112.82M
Shareholders' Equity	$436.18M	$292.54M	$422.18M	$512.23M	$580.63M	$621.41M	$592.01M	$666.88M	$743.40M	$806.48M	$865.27M
Cash & Equivalents	$38.63M	$51.69M	$75.22M	$83.16M	$69.25M	$154.76M	$109.93M	$61.90M	$74.36M	$96.04M	$84.51M
Operating Cash Flow	-$102.20M	-$149.25M	-$200.30M	-$237.73M	n/a	n/a	n/a	-$220.52M	n/a	n/a	n/a
Capital Expenditures	$402.0K	$386.0K	$694.0K	$1.52M	n/a	n/a	n/a	$5.19M	n/a	n/a	n/a
Free Cash Flow	-$102.60M	-$149.63M	-$200.99M	-$239.25M	n/a	n/a	n/a	-$225.71M	n/a	n/a	n/a
Shares Outstanding	345.35M	229.41M	212.21M	168.64M	168.18M	167.13M	145.74M	144.44M	144.03M	143.72M	143.57M
Dividends Per Share	n/a	$0.00	$0.00	$0.00	n/a	n/a	n/a	$0.00	n/a	n/a	n/a
Weighted Average Diluted Shares	n/a	220.62M	194.81M	156.93M	n/a	n/a	n/a	143.15M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.87	-$1.32	-$2.09	n/a	n/a	n/a	-$2.38	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView